TY - JOUR
T1 - Levodopa-carbidopa intestinal gel for advanced Parkinson's disease
T2 - Impact of LRRK2 and GBA1 mutations
AU - Thaler, Avner
AU - Anis, Saar
AU - Ponger, Penina
AU - Fay-Karmon, Tsviya
AU - Livneh, Vered
AU - Faust-Socher, Achinoam
AU - Greenbaum, Lior
AU - Reiner, Johnathan
AU - Hilel, Ariela
AU - Shabtai, Hertzel
AU - Alcalay, Roy N.
AU - Djaldetti, Ruth
AU - Hassin-Baer, Sharon
AU - Ezra, Adi
AU - Mirelman, Anat
AU - Giladi, Nir
AU - Gurevich, Tanya
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/10
Y1 - 2024/10
N2 - Background: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG). Objective: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD. Methods: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status. Results: Fifty-two iPD, 15 LRRK2-PD and 23 GBA1-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. GBA1-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with LRRK2-PD and iPD. LRRK2-PD and iPD had significantly longer duration of LCIG treatment compared with GBA1-PD (p < 0.01). Conclusion: Overall, LCIG treatment was well tolerated in LRRK2-PD and GBA1-PD. GBA1-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.
AB - Background: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG). Objective: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD. Methods: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status. Results: Fifty-two iPD, 15 LRRK2-PD and 23 GBA1-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. GBA1-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with LRRK2-PD and iPD. LRRK2-PD and iPD had significantly longer duration of LCIG treatment compared with GBA1-PD (p < 0.01). Conclusion: Overall, LCIG treatment was well tolerated in LRRK2-PD and GBA1-PD. GBA1-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.
KW - GBA1
KW - Levodopa-carbidopa intestinal gel
KW - Parkinson's disease LRRK2
UR - http://www.scopus.com/inward/record.url?scp=85202199686&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2024.107115
DO - 10.1016/j.parkreldis.2024.107115
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39208588
AN - SCOPUS:85202199686
SN - 1353-8020
VL - 127
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
M1 - 107115
ER -